NCT03465644

TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI

Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2,018 (actual)
• Sponsor: Duk-Woo Park, MD · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (\<6-month post-PCI) intensified (low-dose ticagrelor \[120 mg loading, then 60 mg bid maintenance\] and aspirin) and late (\>6-month post-PCI) deescalated (clopidogrel alone) strategy in patients undergoing high-risk complex PCI as compared with standard Dual Antiplatelet Therapy(aspirin and clopidogrel for 12 months).

Conditions

• Coronary Stenoses

Interventions

Type	Name	Description
DRUG	Tailored antithrombotic strategy	Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
DRUG	Conventional antithrombotic strategy	Clopidogrel + aspirin for 12months

Timeline

• Start date: 2019-02-12
• Primary completion: 2025-02-13
• Completion: 2025-02-13
• First posted: 2018-03-14
• Last updated: 2025-06-06

Locations

22 sites across 1 country: South Korea